R Squared’s Atossa Therapeutics ATOS Stock Holding History

R Squared’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,873	Closed	-$16.6K	–	499
2025 Q4	$16.6K	Buy	+1,873	New	+$23.7K	0.01%	499
2025 Q1	–	Sell	-68	Closed	-$963	–	392
2024 Q4	$963	Buy	+68	New	+$1.33K	﹤0.01%	1515

Other funds holding ATOS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

R Squared's ATOS Position: Q1 2026 in Review

R Squared sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 1,873 shares — an estimated $16.6K sold.

R Squared first reported a position in ATOS in Q4 2024 and held it in 2 quarters. The position peaked at $16.6K in Q4 2025. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

R Squared reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
R Squared sold 1,873 Atossa Therapeutics shares in Q1 2026, an estimated $16.6K.
R Squared first reported a position in Atossa Therapeutics in Q4 2024 and held it in 2 quarters.
R Squared's Atossa Therapeutics position peaked at $16.6K in Q4 2025.
33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.